Edition:
United States

OraSure Technologies Inc (OSUR.OQ)

OSUR.OQ on NASDAQ Stock Exchange Global Select Market

14.84USD
26 May 2017
Change (% chg)

$0.04 (+0.27%)
Prev Close
$14.80
Open
$14.79
Day's High
$14.90
Day's Low
$14.74
Volume
128,480
Avg. Vol
315,242
52-wk High
$15.71
52-wk Low
$5.57

Latest Key Developments (Source: Significant Developments)

Orasure announces Q1 revenue $32.5 million
Wednesday, 3 May 2017 04:00pm EDT 

May 3 (Reuters) - Orasure Technologies Inc :Orasure announces 2017 first quarter financial results.Q1 earnings per share $0.21.Q1 revenue $32.5 million versus I/B/E/S view $31.2 million.Q1 earnings per share view $0.18 -- Thomson Reuters I/B/E/S.Sees Q2 2017 earnings per share $0.07 to $0.08.Sees Q2 2017 revenue $36.5 million to $37 million.Q2 earnings per share view $0.06, revenue view $34.4 million -- Thomson Reuters I/B/E/S.  Full Article

OraSure receives global fund classification to enable HIV self-test procurement
Wednesday, 1 Mar 2017 06:00am EST 

OraSure Technologies Inc : OraSure Technologies Inc - OraSure receives global fund classification to enable HIV self-test procurement .OraSure Technologies Inc - Classification facilitates product procurement for 12 months with global fund and/or UNITAID resources.  Full Article

OraSure announces 2016 fourth quarter and full-year financial results
Wednesday, 8 Feb 2017 04:00pm EST 

OraSure Technologies Inc : OraSure announces 2016 fourth quarter and full-year financial results . Q4 earnings per share $0.13 . Q4 revenue $35.5 million versus I/B/E/S view $34.2 million . Q4 earnings per share view $0.06 -- Thomson Reuters I/B/E/S . Sees Q1 2017 earnings per share $0.17 to $0.18 . Sees Q1 2017 revenue $31 million to $31.5 million . OraSure Technologies Inc says quarterly guidance also includes after-tax impact of a $12.5 million litigation settlement recently announced by company .Q1 earnings per share view $0.03, revenue view $29.9 million -- Thomson Reuters I/B/E/S.  Full Article

Orasure Technologies appoints Stephen Tang as chairman of the board of directors
Tuesday, 15 Nov 2016 06:00am EST 

Orasure Technologies Inc : Orasure Technologies Inc- appointment of Stephen S. Tang, as chairman of company's board of directors effective November 14, 2016 . Orasure Technologies Inc- retirement of Douglas G. Watson as a director and chairman of board, effective November 13, 2016 .Orasure Technologies appoints Stephen S. Tang, PH.D. As chairman of the board of directors.  Full Article

Orasure awarded up to $16.6 mln to advance rapid zika tests
Tuesday, 23 Aug 2016 04:00pm EDT 

Orasure Technologies Inc : Awarded up to $16.6 million to advance rapid zika tests . Six-year, multi-phased contract includes an initial commitment of $7.0 million .Contract includes options for upto additional $9.6 million to fund evaluation of additional product enhancements,regulatory activities.  Full Article

Orasure Technologies reports earnings per share of $0.07
Wednesday, 3 Aug 2016 04:00pm EDT 

Orasure Technologies Inc : Orasure announces 2016 second quarter financial results . Q2 earnings per share $0.07 . Q2 revenue $31.4 million versus I/B/E/S view $31.2 million . Q2 earnings per share view $0.05 -- Thomson Reuters I/B/E/S . Sees Q3 2016 earnings per share $0.07 to $0.08 . Orasure Technologies Inc sees consolidated net income for Q3 between $0.07 and $0.08 per share . Orasure Technologies Inc says company expects consolidated net revenues for Q3 to range from $31.25 million to $31.75 million .Q3 earnings per share view $0.08, revenue view $34.6 million -- Thomson Reuters I/B/E/S.  Full Article

OraSure Technologies Inc gives Q4 2015 mixed guidance
Wednesday, 4 Nov 2015 04:00pm EST 

OraSure Technologies Inc:Expects Q4 2015 consolidated net revenues to range from $29.5 to $30.0 million and is projecting a consolidated net income of between $0.03 and $0.04 per share.Q4 2015 revenue of $31 million and EPS of $0.01 - Thomson Reuters I/B/E/S.  Full Article

OraSure Technologies Inc provides update on oraquick ebola rapid antigen test business
Tuesday, 29 Sep 2015 06:00am EDT 

OraSure Technologies Inc:Provides update on oraquick ebola rapid antigen test business.Says made progress regarding the commercialization of its oraquick ebola rapid antigen test.Says Hhs' centers for disease control and prevention will purchase about $1.5 million of the company's oraquick ebola rapid antigen test.Cdc purchase is expected to be fulfilled by the end of 2015.Cdc is purchasing the oraquick ebola rapid antigen tests for field testing in west Africa.U.S. department of health and human services to provide $7.2 million in additional funding for co's oraquick ebola rapid antigen test.Funding will be used for clinical and regulatory activities required to request FDA 510(k) clearance for product.  Full Article

OraSure Technologies Inc gives Q3 2015 guidance; revenue guidance above analysts' estimates
Wednesday, 5 Aug 2015 04:14pm EDT 

OraSure Technologies Inc:Expects Q3 2015 consolidated net revenues to range from $29.5 to $30.0 million and is projecting a consolidated bottom line performance of breakeven to a consolidated net loss of ($0.01) per share.Q3 2015 revenue of $29.3 million and EPS of $0.00 - Thomson Reuters I/B/E/S.  Full Article

OraSure Technologies Inc received FDA emergency use authorization for ebola diagnostic test
Monday, 3 Aug 2015 06:00am EDT 

OraSure Technologies Inc:Receives FDA emergency use authorization for ebola rapid diagnostic test.Says test has not been cleared or approved by FDA.Test authorized by FDA under EUA for use by laboratories,facilities adequately equipped, trained, capable of testing for ebola.Received U.S. FDA emergency use authorization for oraquick ebola rapid antigen test for use with fingerstick, venous whole blood.  Full Article

More From Around the Web